Illumina Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Illumina de 67% y 7.5% por año respectivamente. Se prevé que el BPA crezca en un 67.5% al año. Se espera que la rentabilidad financiera sea de 8.8% en 3 años.

Información clave

67.0%

Tasa de crecimiento de los beneficios

67.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	16.4%
Tasa de crecimiento de los ingresos	7.5%
Rentabilidad financiera futura	8.8%
Cobertura de analistas	Good
Última actualización	29 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22

The Big Trends: New Frontiers in Healthcare

Jul 13

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14

Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?

Dec 30

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?

Dec 02

These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Oct 27

Illumina, GenoScreen collaborate on genomic testing for drug-resistant TB

Oct 18

Illumina in research collaboration with AstraZeneca on drug target discovery

Oct 11

Illumina Engages Obama To Push Its Customers' Reimbursement Agenda

Sep 29

Illumina to appeal EU decision to block GRAIL acquisition

Sep 06

Illumina Needs Grail, But May Lose It

Aug 30

Illumina added to positive catalyst watch at Citi despite Q2 miss

Aug 22

Illumina up 9% following drop after Q2 earnings

Aug 15

Is It Too Late To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Aug 08

Still Avoiding Illumina Stock

Aug 05

Illumina, Grail deal unlikely to get EU nod – Reuters

Jul 27

Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 48% Discount?

Jul 22

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ILMN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5,413	523	873	978	10
12/31/2025	4,955	286	732	927	18
12/31/2024	4,515	-137	338	579	19
12/31/2023	4,504	-1,161	282	478	N/A
10/1/2023	4,465	-1,125	168	401	N/A
7/2/2023	4,461	-4,186	-224	210	N/A
4/2/2023	4,448	-4,487	-228	230	N/A
1/1/2023	4,584	-4,404	-74	392	N/A
10/2/2022	4,700	-4,153	79	527	N/A
7/3/2022	4,693	-20	53	307	N/A
4/3/2022	4,656	701	208	435	N/A
1/2/2022	4,526	762	337	545	N/A
10/3/2021	4,280	907	469	669	N/A
7/4/2021	3,966	769	898	1,094	N/A
4/4/2021	3,473	630	890	1,081	N/A
1/3/2021	3,239	656	891	1,080	N/A
9/27/2020	3,238	638	933	1,117	N/A
6/28/2020	3,351	693	1,046	1,231	N/A
3/29/2020	3,556	942	941	1,134	N/A
12/29/2019	3,543	1,002	842	1,051	N/A
9/29/2019	3,458	973	691	908	N/A
6/30/2019	3,405	938	701	933	N/A
3/31/2019	3,397	851	823	1,085	N/A
12/30/2018	3,333	826	846	1,142	N/A
9/30/2018	3,243	684	829	1,136	N/A
7/1/2018	3,103	648	752	1,079	N/A
4/1/2018	2,936	567	643	962	N/A
12/31/2017	2,752	725	563	875	N/A
10/1/2017	2,594	775	N/A	843	N/A
7/2/2017	2,487	741	N/A	784	N/A
4/2/2017	2,424	730	N/A	848	N/A
1/1/2017	2,398	454	N/A	779	N/A
10/2/2016	2,371	440	N/A	757	N/A
7/3/2016	2,314	430	N/A	762	N/A
4/3/2016	2,253	415	N/A	692	N/A
1/3/2016	2,220	462	N/A	786	N/A
9/27/2015	2,141	510	N/A	560	N/A
6/28/2015	2,071	486	N/A	524	N/A
3/29/2015	1,979	430	N/A	531	N/A
12/28/2014	1,861	353	N/A	501	N/A
9/28/2014	1,736	281	N/A	488	N/A
6/29/2014	1,612	219	N/A	425	N/A
3/30/2014	1,511	208	N/A	336	N/A
12/29/2013	1,421	125	N/A	386	N/A
9/29/2013	1,343	117	N/A	338	N/A
6/30/2013	1,272	115	N/A	307	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ILMN sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que ILMN sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ILMN sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (7.5% al año) de ILMN crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 7.5% al año) de ILMN crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ILMN sea baja dentro de 3 años (8.8%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Illumina Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 25%

Consensus EPS estimates upgraded to US$0.56 loss

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Price target decreased by 15% to US$168

Recent updates

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Consensus EPS estimates fall by 25%

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Consensus EPS estimates upgraded to US$0.56 loss

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

CEO & Director recently bought US$992k worth of stock

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Full year 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 20% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Price target decreased by 15% to US$168

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

Price target decreased by 9.4% to US$203

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Price target decreased by 7.0% to US$224

Second quarter 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023

The Big Trends: New Frontiers in Healthcare

Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Illumina, Inc. Announces CEO Changes

Illumina, Inc. Announces Board Changes

Illumina Unveils AI Software to Predict Disease-Causing Genetic Mutations in Patients

Illumina, Inc. Announces Board Changes

Chief Commercial Officer recently sold US$1.0m worth of stock

Chief Commercial Officer notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Chief of Global Operations exercised options and sold US$83k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Illumina Appoints Joydeep Goswami as Chief Financial Officer

Chief Commercial Officer notifies of intention to sell stock

Illumina, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?

Insufficient new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Illumina Provides Earnings Guidance for the Full Year of 2022

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Illumina, GenoScreen collaborate on genomic testing for drug-resistant TB

Chief Commercial Officer notifies of intention to sell stock

Illumina in research collaboration with AstraZeneca on drug target discovery

Illumina, Inc. to Report Q3, 2022 Results on Nov 03, 2022